The global respiratory monitoring devices market size was USD 14.05 billion in 2023, estimated at USD 15.38 billion in 2024 and is anticipated to reach around USD 37.09 billion by 2034, expanding at a CAGR of 10.19% from 2024 to 2034.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Respiratory Monitoring Devices Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Respiratory Monitoring Devices Market, by Indication Type, 2024-2034
8.1.1. Sleep Apnea
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. COPD
8.1.2.1. Market Revenue and Forecast (2021-2034)
8.1.3. Asthma
8.1.3.1. Market Revenue and Forecast (2021-2034)
8.1.4. Infectious Disease
8.1.4.1. Market Revenue and Forecast (2021-2034)
9.1. Respiratory Monitoring Devices Market, by Device, 2024-2034
9.1.1. Capnography
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Peak Flow Meters
9.1.2.1. Market Revenue and Forecast (2021-2034)
9.1.3. Pulse Oximeters
9.1.3.1. Market Revenue and Forecast (2021-2034)
9.1.4. Spirometers
9.1.4.1. Market Revenue and Forecast (2021-2034)
9.1.5. Gas Analyzers
9.1.5.1. Market Revenue and Forecast (2021-2034)
9.1.6. Polysomnography
9.1.6.1. Market Revenue and Forecast (2021-2034)
9.1.7. Others
9.1.7.1. Market Revenue and Forecast (2021-2034)
10.1. Respiratory Monitoring Devices Market, by End User, 2024-2034
10.1.1. Hospitals
10.1.1.1. Market Revenue and Forecast (2021-2034)
10.1.2. Clinics
10.1.2.1. Market Revenue and Forecast (2021-2034)
10.1.3. Homecare
10.1.3.1. Market Revenue and Forecast (2021-2034)
11.1. North America
11.1.1. Market Revenue and Forecast, by Indication (2021-2034)
11.1.2. Market Revenue and Forecast, by Device (2021-2034)
11.1.3. Market Revenue and Forecast, by End User (2021-2034)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Indication (2021-2034)
11.1.4.2. Market Revenue and Forecast, by Device (2021-2034)
11.1.4.3. Market Revenue and Forecast, by End User (2021-2034)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Indication (2021-2034)
11.1.5.2. Market Revenue and Forecast, by Device (2021-2034)
11.1.5.3. Market Revenue and Forecast, by End User (2021-2034)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Indication (2021-2034)
11.2.2. Market Revenue and Forecast, by Device (2021-2034)
11.2.3. Market Revenue and Forecast, by End User (2021-2034)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Indication (2021-2034)
11.2.4.2. Market Revenue and Forecast, by Device (2021-2034)
11.2.4.3. Market Revenue and Forecast, by End User (2021-2034)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Indication (2021-2034)
11.2.5.2. Market Revenue and Forecast, by Device (2021-2034)
11.2.5.3. Market Revenue and Forecast, by End User (2021-2034)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Indication (2021-2034)
11.2.6.2. Market Revenue and Forecast, by Device (2021-2034)
11.2.6.3. Market Revenue and Forecast, by End User (2021-2034)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Indication (2021-2034)
11.2.7.2. Market Revenue and Forecast, by Device (2021-2034)
11.2.7.3. Market Revenue and Forecast, by End User (2021-2034)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Indication (2021-2034)
11.3.2. Market Revenue and Forecast, by Device (2021-2034)
11.3.3. Market Revenue and Forecast, by End User (2021-2034)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Indication (2021-2034)
11.3.4.2. Market Revenue and Forecast, by Device (2021-2034)
11.3.4.3. Market Revenue and Forecast, by End User (2021-2034)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Indication (2021-2034)
11.3.5.2. Market Revenue and Forecast, by Device (2021-2034)
11.3.5.3. Market Revenue and Forecast, by End User (2021-2034)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Indication (2021-2034)
11.3.6.2. Market Revenue and Forecast, by Device (2021-2034)
11.3.6.3. Market Revenue and Forecast, by End User (2021-2034)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Indication (2021-2034)
11.3.7.2. Market Revenue and Forecast, by Device (2021-2034)
11.3.7.3. Market Revenue and Forecast, by End User (2021-2034)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Indication (2021-2034)
11.4.2. Market Revenue and Forecast, by Device (2021-2034)
11.4.3. Market Revenue and Forecast, by End User (2021-2034)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Indication (2021-2034)
11.4.4.2. Market Revenue and Forecast, by Device (2021-2034)
11.4.4.3. Market Revenue and Forecast, by End User (2021-2034)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Indication (2021-2034)
11.4.5.2. Market Revenue and Forecast, by Device (2021-2034)
11.4.5.3. Market Revenue and Forecast, by End User (2021-2034)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Indication (2021-2034)
11.4.6.2. Market Revenue and Forecast, by Device (2021-2034)
11.4.6.3. Market Revenue and Forecast, by End User (2021-2034)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Indication (2021-2034)
11.4.7.2. Market Revenue and Forecast, by Device (2021-2034)
11.4.7.3. Market Revenue and Forecast, by End User (2021-2034)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Indication (2021-2034)
11.5.2. Market Revenue and Forecast, by Device (2021-2034)
11.5.3. Market Revenue and Forecast, by End User (2021-2034)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Indication (2021-2034)
11.5.4.2. Market Revenue and Forecast, by Device (2021-2034)
11.5.4.3. Market Revenue and Forecast, by End User (2021-2034)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Indication (2021-2034)
11.5.5.2. Market Revenue and Forecast, by Device (2021-2034)
11.5.5.3. Market Revenue and Forecast, by End User (2021-2034)
12.1. Medtronic
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. GE Healthcare
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Masimo
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Philips Healthcare
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Welch Allyn, Inc.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Smiths Medical
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. MGC Diagnostics Corporation
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Novelda AS
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Dragerwerk AG & Co. KGaA
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Nihon Kohden Corporation
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client